Pleiotropic targets that are evoked during inflammatory and degenerative conditions of the RPE, such as binding sites for the predicted EMT drivers SNAIL1/2, TWIST1, ZEB, and bHLH family members, may provide potential avenues to address subretinal fibrosis in nvAMD, proliferative diabetic retinopathy, and, potentially, chemoresistance in cancer via pharmacogenomic, targeted therapies. The gene discussed is TWIST1; the disease is cancer.